https://pharma.economictimes.indiatimes.com/news/pharma-industry/biogen-strikes-850-million-immune-disease-drug-deal-with-chinas-tj-biopharma/130411585
Biogen Secures $850 Million Licensing Deal for Immune Disease Drug Felzartamab in Greater China,...
Biogen has entered an $850 million licensing agreement with TJ Biopharma to market Felzartamab, an investigational therapy for immune-mediated diseases in...
https://pubmed.ncbi.nlm.nih.gov/38804514/
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences;...
randomizedphasetrial